- IN₹13.44bn
- IN₹13.37bn
- IN₹2.27bn
- 74
- 10
- 80
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.47 | ||
| Price to Tang. Book | 9.82 | ||
| Price to Free Cashflow | 118.59 | ||
| Price to Sales | 5.25 | ||
| EV to EBITDA | 22.59 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 31.28% | ||
| Return on Equity | 27.81% | ||
| Operating Margin | 18.81% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 659.29 | 908.06 | 1,161.22 | 1,838.37 | 2,271.14 | n/a | n/a | 40.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +55.28 | +5.53 | +24.34 | +111.69 | +23.73 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beta Drugs Limited is an India-based company, which is engaged in manufacturing of the wide range of anti-cancer drugs in India. The Company operates through manufacturing of Oncology medicines segment. The Company offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, lung, head, and neck, colorectal, ovarian, gastric, brain, testicular renal, prostate, leukemia, lymphoma, myeloma, supportive. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ARBAZ, FISTENT, BUSFAN, Triodelta and others. The Company's subsidiaries include Adley Lab Limited, Adley Formulations Private Limited.
Directors
- Vijay Batra CHM (63)
- Jayant Kumar CFO (43)
- Rajni Brar CCO (31)
- Neeraj Batra EDR (58)
- Rahul Batra EDR (33)
- Varun Batra EDR (32)
- Balwant Singh EDR (47)
- Nipun Arora IND (33)
- Manmohan Khanna IND (63)
- Rohit Parti IND (41)
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- September 21st, 2005
- Public Since
- October 12th, 2017
- No. of Employees
- 315
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 9,613,790
- Address
- Sco 184, Sector 5, Panchkula, PANCHKULA, 134114
- Web
- https://betadrugslimited.com/
- Phone
- +91 17225854813
- Auditors
- M/s Kalra Rai & Associates
Upcoming Events for BETA
Similar to BETA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Beta Drugs share price?
As of Today at 19:03 UTC, shares in Beta Drugs are trading at IN₹1,398.50. This share price information is delayed by 15 minutes.
How has the Beta Drugs share price performed this year?
Shares in Beta Drugs last closed at IN₹1,398.50 and the price had moved by +77.03% over the past 365 days. In terms of relative price strength the Beta Drugs share price has outperformed the S&P BSE 100 Index by +37.3% over the past year.
What are the analyst and broker recommendations for Beta Drugs?
There is no consensus recommendation for this security.
What is the Beta Drugs dividend yield?
Beta Drugs does not currently pay a dividend.
Does Beta Drugs pay a dividend?
Beta Drugs does not currently pay a dividend.
When does Beta Drugs next pay dividends?
Beta Drugs does not currently pay a dividend.
How do I buy Beta Drugs shares?
To buy shares in Beta Drugs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Beta Drugs?
As of the previous close price of IN₹1,398.50, shares in Beta Drugs had a market capitalisation of IN₹13.44bn.
Where are Beta Drugs shares listed?
Here are the trading details for Beta Drugs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BETA
What kind of share is Beta Drugs?
Based on an overall assessment of its quality, value and momentum Beta Drugs is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Beta Drugs share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Beta Drugs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beta Drugs. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +30.11%.
As of the last closing price of IN₹1,398.50, shares in Beta Drugs were trading +22.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Beta Drugs PE Ratio?
The Beta Drugs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹1,398.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Beta Drugs?
Beta Drugs' management team is headed by:
- Vijay Batra - CHM
- Jayant Kumar - CFO
- Rajni Brar - CCO
- Neeraj Batra - EDR
- Rahul Batra - EDR
- Varun Batra - EDR
- Balwant Singh - EDR
- Nipun Arora - IND
- Manmohan Khanna - IND
- Rohit Parti - IND